The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.

The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.

The Food and Drug Administration has approved expanded use of leucovorin calcium tablets for treating cerebral folate deficiency, a rare disorder.